Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Albireo Pharma (NASDAQ:ALBO) from a sell rating to a hold rating in a research note released on Thursday morning, BidAskClub reports.

A number of other brokerages have also issued reports on ALBO. William Blair restated a buy rating on shares of Albireo Pharma in a research note on Monday, July 15th. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Wedbush set a $9.00 price objective on shares of GameStop and gave the stock a buy rating in a report on Thursday, July 11th. HC Wainwright reaffirmed a buy rating and issued a $60.00 price objective on shares of Beyondspring in a report on Wednesday, July 10th. Finally, Cowen reaffirmed a market perform rating and issued a $99.00 price objective (up previously from $97.00) on shares of United Continental in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $54.25.

Shares of NASDAQ:ALBO opened at $28.22 on Thursday. The stock has a fifty day moving average of $31.51. The company has a market capitalization of $339.74 million, a price-to-earnings ratio of -7.16 and a beta of 1.56. Albireo Pharma has a 12-month low of $19.10 and a 12-month high of $38.69.



Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.20 million. Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%. As a group, equities analysts predict that Albireo Pharma will post -5.99 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Albireo Pharma by 356.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,599 shares during the period. Bank of America Corp DE boosted its holdings in shares of Albireo Pharma by 87.6% during the fourth quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 3,020 shares during the period. Rhumbline Advisers boosted its holdings in shares of Albireo Pharma by 40.2% during the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 3,743 shares during the period. Hartwell J M Limited Partnership boosted its holdings in shares of Albireo Pharma by 17.8% during the first quarter. Hartwell J M Limited Partnership now owns 14,250 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 2,150 shares during the period. Finally, Private Advisors LLC boosted its holdings in shares of Albireo Pharma by 3.4% during the first quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after acquiring an additional 506 shares during the period. 70.42% of the stock is owned by hedge funds and other institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Further Reading: How accurate is the Rule of 72?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.